Glucagon Trial "Graded Insulin Suppression Test P&F" Marked Completed

A Phase 1 clinical trial involving glucagon has been updated to completed status as of October 16, 2026. The trial, registered as NCT06592261 and titled "Graded Insulin Suppression Test P&F," is listed on ClinicalTrials.gov. Glucagon remains an approved compound, and this update pertains specifically to the trial's status rather than to its regulatory standing. No results or outcome data were included in this update, only the change in trial status to completed. The trial is categorized as Phase 1, which typically focuses on initial evaluation of a compound or test procedure. No efficacy or safety conclusions can be drawn from a status update alone. Readers should note that completion of a trial indicates the study has concluded its planned activities, not that findings have been published or reviewed. Further details, including any eventual results, would be expected to appear in subsequent updates to the trial registry or in a related publication. For additional context on glucagon, including its approved uses and general background, readers can consult the compound overview.